(PDF) The First Biosimilar Approved for the Treatment of

The First Biosimilar Approved for the Treatment of Osteoporosis: Results of a Comparative Pharmacokinetic/Pharmacodynamic Study

Osteoporosis International - United Kingdom

doi 10.1007/s00198-018-4741-0

Full Text

Abstract

Available in full text

Categories

Date

October 24, 2018

Authors

Publisher

Springer Science and Business Media LLC

Related search

Filgrastim-SNDZ Debuts as the First Biosimilar Approved in United States

Journal of Community and Supportive Oncology

English

Pharmacokinetic and Pharmacodynamic Considerations of Rifamycin Antibiotics for the Treatment of Tuberculosis

Expert Opinion on Drug Metabolism and Toxicology

English

Pharmacokinetic and Pharmacodynamic Evaluation of Rivaroxaban: Considerations for the Treatment of Venous Thromboembolism

Thrombosis Journal

English

A Comparative Study Between Intravenous and Oral Alendronate Administration for the Treatment of Osteoporosis

Multidisciplinary

English

FDA-Approved Biosimilar Insulin

Journal of diabetes science and technology

Internal Medicine

Biomedical Engineering

English

Comparison of the Pharmacodynamic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology

English

Target‐mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐informed Dose Selection for the First‐in‐human Study of AVB‐S6‐500

Clinical and Translational Science

Molecular Biology

English

Osteoporosis Treatment Adherence: Results From a Retrospective Cohort Study

Nauchno-Prakticheskaya Revmatologiya

English

Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study

International Journal of Endocrinology

Autonomic Systems

English